Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Leukemia

Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission

Bone Marrow Transplantation volume 48, pages 383–389 (2013)Cite this article

Subjects

Abstract

The most effective post-first CR1 treatment for patients with AML, allogenic hematopoietic SCT (allo-HSCT) or autologous hematopoietic SCT (HSCT), remains to be conclusively determined. This study aimed to compare the effectiveness of treatment with allo-HSCT or auto-HSCT in patients with AML after CR1. We retrospectively reviewed medical records of 127 patients with AML who received allo- (n=52) or auto-HSCT (n=75) after achieving CR1 at a single medical center. The disease-free and overall survival rates and complications were analyzed. During a median follow-up of 1215 days, all patients (100%) in allo-HSCT group and 94.7% of patients in the auto-HSCT group had successful outcomes. The disease-free survival rates were 65.3% and 50.6% for allo- and auto-HSCT groups, respectively (P=0.158), while the overall survival rates were 65.3% and 54.9%, respectively (P=0.486). The recurrence rate was higher with auto-HSCT, whereas the GVHD only happened with allo-HSCT. In conclusion, auto-HSCT was as effective as allo-HSCT for the treatment of patients with AML after CR1. This is encouraging given that allo-HSCT is not always feasible in China because of a lack of matching donors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349–2361.

    Article  CAS  Google Scholar 

  2. Bleakley M, Lau L, Shaw PJ, Kaufman A . Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 2002; 29: 843–852.

    Article  CAS  Google Scholar 

  3. Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Shpilberg O . Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 2004; 28: 605–612.

    Article  CAS  Google Scholar 

  4. Nathan PC, Sung L, Crump M, Beyene J . Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96: 38–45.

    Article  CAS  Google Scholar 

  5. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037–6042.

    Article  CAS  Google Scholar 

  6. Gorin NC . Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073–1090.

    CAS  PubMed  Google Scholar 

  7. Oran B, Weisdorf DJ . Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 2011; 18: 395–400.

    Article  Google Scholar 

  8. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721–1731.

    Article  CAS  Google Scholar 

  9. Zhou J . Comparison of two pretreatment protocol for allogeneic bone marrow transplantation. Chin J Hematol 1996; 17: 64–66.

    CAS  Google Scholar 

  10. Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011; 17: 401–411.

    Article  Google Scholar 

  11. Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Br J Haematol 1998; 102: 1344–1353.

    Article  CAS  Google Scholar 

  12. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232–1240.

    Article  CAS  Google Scholar 

  13. Willemze R, Suciu S, Mandelli F, de Witte T, Amador S . Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. Ann Hematol 2004; 83 (Suppl 1): S134.

    PubMed  Google Scholar 

  14. Hsieh YY, Hong YC, Hsiao LT, Yu YB, Liu JH, Gau JP et al. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia. Eur J Haematol 2011; 86: 237–245.

    Article  Google Scholar 

  15. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T . Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51: 50–60.

    Article  Google Scholar 

  16. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493–500.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the nurses and residents of the ward for their dedication to the patients.

Authors contributions: Hong-hua Li: donor search and coordination; Shu-hong Wang: data management; Yu Zhao and Quan-shun Wang: editorial assistance; Jian Bo, Wen-rong Huang and Chun-ji Gao: continuous support; Yu Jing: writing the draft; and Li Yu: careful designing and revising the paper. This work was supported by grants from China (90919044, 30971297, 81170518 and 07MP03).

Author information

Authors and Affiliations

  1. Department of Hematology, Chinese PLA General Hospital, Beijing, PR China

    Y Jing, H Li, Y Zhao, J Bo, S Wang, Q Wang, W Huang, C Gao & L Yu

Authors
  1. Y Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Yu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jing, Y., Li, H., Zhao, Y. et al. Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission. Bone Marrow Transplant 48, 383–389 (2013). https://doi.org/10.1038/bmt.2012.154

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.154

Keywords

Search

Advanced search

Quick links